A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors
- 30 September 2000
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 29 (1), 65
- https://doi.org/10.1016/s0169-5002(00)80208-1